Exelixis, Inc. (NASDAQ:EXEL) Director Sells $425,884.80 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Exelixis Trading Up 5.0 %

NASDAQ:EXEL opened at $36.85 on Friday. The firm has a market cap of $10.31 billion, a PE ratio of 20.82, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. The stock has a fifty day moving average price of $34.20 and a 200 day moving average price of $31.23. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $37.59.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on EXEL. JMP Securities reissued a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. Citigroup raised their target price on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Guggenheim reissued a “buy” rating and set a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Finally, StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Coppell Advisory Solutions LLC purchased a new stake in Exelixis during the 4th quarter worth about $25,000. V Square Quantitative Management LLC purchased a new stake in Exelixis during the 3rd quarter worth about $30,000. Colonial Trust Co SC lifted its holdings in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after buying an additional 765 shares during the last quarter. USA Financial Formulas purchased a new stake in Exelixis during the 4th quarter worth about $32,000. Finally, Principal Securities Inc. lifted its holdings in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after buying an additional 373 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.